Merck Serono, J&J Step Up Investment For Local Chinese Market With Manufacturing Sites
This article was originally published in PharmAsia News
Despite ongoing compliance probes, decelerating growth and continuing price pressure, Merck KGAA and Johnson & Johnson unveil bold localization plans in China with a fresh investment worth millions. They see the need to support essential drug supply, introduce new products and accelerate product registration in China.
You may also be interested in...
Deal could position the pharma giant to eventually become a sixth major player in the worldwide vaccine space.
After winning a major procurement contract, BeiGene now may need to find an alternative manufacturing site for Celgene's Abraxane to supply China.
A former pharma executive shares views with Scrip about the coronavirus in China, the challenges facing corporations and individuals in a rapidly changing world and coming threats that could potentially cause even more damage than the pandemic.